In our study, in vivo genome-wide CRISPR screening and RNA-seq for clinical BC tissues identified ENO1 as a regulator of antitumor-tumor immunity and sensitivity to anti-PD-L1 therapy. This evidence concerns the gene CD274 and breast cancer.